



Personalized Medicine in Hematological Diseases

Guest Editors:

Prof. Dr. Dolors Colomer

1. Department of Pathology,
Hematopathology Unit, Hospital
Clinic, Barcelona, Spain

2. Therapeutic Targets in
Lymphoid Malignancies Team,
Institut d'Investigacions
Biomèdiques August Pi i Sunyer
(IDIBAPS), CIBERONC, Barcelona,
Spain

Dr. Laia Rosich

Therapeutic targets in lymphoid
malignancies team, Institut
d'Investigacions Biomèdiques
August Pi i Sunyer (IDIBAPS),
CIBERONC, Barcelona, Spain

Deadline for manuscript
submissions:

closed (31 May 2019)

Message from the Guest Editors

Dear Colleagues,

The high diversity of hematological malignancies is a remarkable challenge for their recognition and diagnosis that requires in most cases multidisciplinary expertise. The clinical and biological heterogeneity of these neoplasms is due, in part, to the cellular and functional complexity of the cell populations, the diversity of genetic and molecular mechanisms involved in their initiation and progression and the interactions with the microenvironment and immune system. Advances in the understanding of these mechanisms in the last two decades have established a solid framework for their precise diagnosis, and provide relevant information for new therapeutic approaches. The application of new generation sequencing (NGS) technologies is revealing a landscape of somatic mutations of unprecedented complexity and with potential direct impact on patients. This Special Issue aims to provide a better comprehension of hematological malignancies and the innovative therapeutic strategies that should fulfill aspirations for a more personalized medicine.

Prof. Dr. Dolors Colomer and Dr. Laia Rosich

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)